We have reevaluated the antibiotic susceptibilities of group A beta-hemolytic streptococci in view of recent reports of a high prevalence of erythromycin resistance in Japan and of an increase in penicillin treatment failures in the United States. A total of 474 isolates recovered during a 2-to 3-month period in 1980 were tested. All were susceptible by microtiter broth dilution to a penicillin concentration of c0.03 ,ug/ml (minimal inhibitory concentration), and 473 were killed by c0.06 ug/ml (minimal bactericidal concentration). Erythromycin minimal inhibitory concentrations showed a bimodal distribution: 95% were -0.06,tg/ ml, and 5% were 21 ,ug/ml. Of the minimal bactericidal concentrations, 21% were 21 ,ug/ml and 3% were :16 ug/ml. Group A beta-hemolytic streptococci remain susceptible to the inhibitory and bactericidal actions of penicillin, thus providing no in vitro explanation for the bacteriological relapses reported in some clinical studies. Unlike the Japanese experience, only 5% of our isolates were resistant to erythromycin (minimal inhibitory concentration, 21 ug/ml); however, 22% were tolerant (ratio of minimal inhibitory/bactericidal concentrations, 232).
Although in vitro resistance to penicillin has not been described for group A beta-hemolytic Streptococcus, a trend of increasing resistance to erythromycin has been reported (2) (3) (4) 9) . Recently some clinicians have noted an increased incidence of treatment failure as compared with data relating to treatment results derived 2 decades ago (6, 7, (10) (11) (12) 14) . In view of these findings, we have evaluated antibiotic susceptibilities of group A beta-hemolytic Streptococcus strains recently isolated from patients in Oklahoma.
MATERIALS AND (13) . Micro-broth dilution tests were performed using the Dynatech MIC 2000 system (Dynatech Laboratories, Inc., Alexandria, Va.) according to the manufacturer's directions. Serial twofold antibiotic dilutions in Mueller-Hinton broth supplemented with 5% sheep blood were contained in a total volume of 0.1 ml per well. Minimal bactericidal concentrations (MBC) were performed using the Dynatech inoculator pin assembly to subculture approximately 0.0015 ml from all wells of the microtiter plate onto a 150-mm petri plate containing 5% sheep blood agar. MBC endpoints were interpreted as wells containing the lowest concentration of antibiotic which yielded no growth after subculture. Quality control of susceptibility testing media was performed with Staphylococcus aureus ATCC 25923.
RESULTS
The accuracy of the broth dilution methodology was verified by performing simultaneous susceptibility determinations by agar dilution on the first 31 isolates. Identical results were obtained for 24/31 and 27/31 strains for penicillin and erythromycin, respectively. Agar and broth dilution minimal inhibitory concentrations (MICs) for both antibiotics were within one dilution for all isolates tested. When single dilution step differences for penicillin (7/31) or erythromycin (4/31) occurred, the micro-broth result was consistently greater than the agar dilution result.
All 474 isolates were susceptible to penicillin at an MIC of c0.03 ,ug/ml, and more than threefourths had an MIC of <0.007 ,ug/ml. None showed tolerance (arbitrarily defined as MBC/ MIC -32) to penicillin (Fig. 1) . Only one isolate required an MBC as high as 0.25 ,ug/ml; the remaining 473 required MBCs of c0.06 ,ug/ml.
Erythromycin MICs, however, showed a bimodal distribution. As seen in Fig. 2 , 95% of isolates required erythromycin MICs of 50.06 ,ug/ml; the remaining 5% required 21 ,ig/ml for inhibition. Cumulative erythromycin MBCs were s0.125 ,ug/ml for 62%, cl fig/ml for 79%, and _16 ,ig/ml for 97% of strains (Fig. 1) . Tolerance (as defined above) to erythromycin was found in 22% of isolates, and erythromycin MICs and MBCs in general showed a much greater disparity than those of penicillin (Fig. 1) . DISCUSSION Despite recent reports from Japan of 62 to 72% resistance of group A beta-hemolytic Streptococcus to erythromycin (5, 9), our study showed a comparatively low (5%) prevalence of erythromycin resistance in Oklahoma. It does, however, reflect a trend of gradually increasing resistance seen in the United States since 1963. Eickhoff and Finland (3) reported no resistance to erythromycin among over 300 strains in 1963; Dixon and Lipinski (2) 520, 1979) . Our study, using 474 isolates from patients with pharyngitis, showed a significant portion (22%) with MIC and MBC disparity for erythromycin, indicating that erythromycin does exhibit more apparent bac- 20, 1981 on June 18, 2017 by guest http://aac.asm.org/ romycin, thus limiting the potential usefulness of this drug in the therapy of group A betahemolytic Streptococcus disease. Although the actual clinical significance of this resistance is yet to be determined, physicians in the United States should be alert to the possibility that we may be experiencing the early phase of streptococcal resistance patterns now seen in other parts of the world.
